Schalper Lab Publications

2022

Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee.Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, Lopez-Rios F, Tsao MS, Yatabe Y, Beasley MB, Yu H, Sholl LM, Brambilla E, Chou TY, Connolly C, Wistuba I, Kerr KM, Lantuejoul S. J Thorac Oncol. 2022 Sep 29; 2022 Sep 29. PMID: 36184066.
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.Moutafi MK, Molero M, Martinez Morilla S, Baena J, Vathiotis IA, Gavrielatou N, Castro-Labrador L, de Garibay GR, Adradas V, Orive D, Valencia K, Calvo A, Montuenga LM, Ponce Aix S, Schalper KA, Herbst RS, Paz-Ares L, Rimm DL, Zugazagoitia J. J Immunother Cancer. 2022 Aug. PMID: 36002182.
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling.Moutafi M, Martinez-Morilla S, Divakar P, Vathiotis I, Gavrielatou N, Aung TN, Yaghoobi V, Fernandez AI, Zugazagoitia J, Herbst RS, Schalper KA, Rimm DL. J Thorac Oncol. 2022 Aug; 2022 Apr 28. PMID: 35490853.
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, Leonardi GC, Plodkowski AJ, Gupta H, Cherniack AD, Tolstorukov MY, Sharma B, Felt KD, Gainor JF, Ravi A, Getz G, Schalper KA, Henick B, Forde P, Anagnostou V, Jänne PA, Van Allen EM, Nishino M, Sholl LM, Christiani DC, Lin X, Rodig SJ, Hellmann MD, Awad MM. JAMA Oncol. 2022 Aug 1. PMID: 35708671.
RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.Hunihan L, Zhao D, Lazowski H, Li M, Qian Y, Abriola L, Surovtseva YV, Muthusamy V, Tanoue LT, Rothberg BEG, Schalper KA, Herbst RS, Wilson FH. Clin Cancer Res. 2022 Jul 15. PMID: 35247929.
Tumor cell SYK expression modulates the tumor immune microenvironment composition in human cancer via TNF-α dependent signaling.Aguirre-Ducler A, Gianino N, Villarroel-Espindola F, Desai S, Tang D, Zhao H, Syrigos K, Trepicchio WL, Kannan K, Gregory RC, Schalper KA. J Immunother Cancer. 2022 Jul. PMID: 35868661.
Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer.Henick BS, Villarroel-Espindola F, Datar I, Sanmamed MF, Yu J, Desai S, Li A, Aguirre-Ducler A, Syrigos K, Rimm DL, Chen L, Herbst RS, Schalper KA. J Immunother Cancer. 2022 Jul. PMID: 35793873.
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA Jr. N Engl J Med. 2022 Jun 23; 2022 Jun 5. PMID: 35660797.
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome.Ding R, Prasanna P, Corredor G, Barrera C, Zens P, Lu C, Velu P, Leo P, Beig N, Li H, Toro P, Berezowska S, Baxi V, Balli D, Belete M, Rimm DL, Velcheti V, Schalper K, Madabhushi A. NPJ Precis Oncol. 2022 Jun 3; 2022 Jun 3. PMID: 35661148.
Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors.Wang X, Barrera C, Bera K, Viswanathan VS, Azarianpour-Esfahani S, Koyuncu C, Velu P, Feldman MD, Yang M, Fu P, Schalper KA, Mahdi H, Lu C, Velcheti V, Madabhushi A. Sci Adv. 2022 Jun 3; 2022 Jun 1. PMID: 35648850.
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer.Lopez de Rodas M, Nagineni V, Ravi A, Datar IJ, Mino-Kenudson M, Corredor G, Barrera C, Behlman L, Rimm DL, Herbst RS, Madabhushi A, Riess JW, Velcheti V, Hellmann MD, Gainor J, Schalper KA. J Immunother Cancer. 2022 Jun. PMID: 35649657.
NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma.Jain D, Nambirajan A, Chen G, Geisinger K, Hiroshima K, Layfield L, Minami Y, Moreira AL, Motoi N, Papotti M, Rekhtman N, Russell PA, Prince SS, Schmitt F, Yatabe Y, Eppenberger-Castori S, Bubendorf L. J Thorac Oncol. 2022 Jun; 2022 Mar 22. PMID: 35331963.
Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis.Chaudhary O, Trotta D, Wang K, Wang X, Chu X, Bradley C, Okulicz J, Maves RC, Kronmann K, Schofield CM, Blaylock JM, Deng Y, Schalper KA, Kaech SM, Agan B, Ganesan A, Emu B. J Immunother Cancer. 2022 Apr. PMID: 35470232.
Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung Cancer.Gavrielatou N, Liu Y, Vathiotis I, Zugazagoitia J, Aung TN, Shafi S, Fernandez A, Schalper K, Psyrri A, Rimm DL. Clin Cancer Res. 2022 Jan 15; 2021 Oct 22. PMID: 34686497.

2021

Tumour antigen-induced T cell exhaustion - the archenemy of immune-hot malignancies.Lopez de Rodas M, Schalper KA. Nat Rev Clin Oncol. 2021 Dec. PMID: 34556846.
Spatial Mapping and Immunomodulatory Role of the OX40/OX40L Pathway in Human Non-Small Cell Lung Cancer.Porciuncula A, Morgado M, Gupta R, Syrigos K, Meehan R, Zacharek SJ, Frederick JP, Schalper KA. Clin Cancer Res. 2021 Nov 15; 2021 Sep 13. PMID: 34518312.
Targeting the Atf7ip-Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity.Hu H, Khodadadi-Jamayran A, Dolgalev I, Cho H, Badri S, Chiriboga LA, Zeck B, Lopez De Rodas Gregorio M, Dowling CM, Labbe K, Deng J, Chen T, Zhang H, Zappile P, Chen Z, Ueberheide B, Karatza A, Han H, Ranieri M, Tang S, Jour G, Osman I, Sucker A, Schadendorf D, Tsirigos A, Schalper KA, Velcheti V, Huang HY, Jin Y, Ji H, Poirier JT, Li F, Wong KK. Cancer Immunol Res. 2021 Nov; 2021 Aug 30. PMID: 34462284.
Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases.Lu BY, Gupta R, Aguirre-Ducler A, Gianino N, Wyatt H, Ribeiro M, Chiang VL, Contessa JN, Adeniran AJ, Jilaveanu LB, Kluger HM, Schalper KA, Goldberg SB. J Immunother Cancer. 2021 Oct. PMID: 34670827.
Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8.de Andrea CE, Ochoa MC, Villalba-Esparza M, Teijeira Á, Schalper KA, Abengozar-Muela M, Eguren-Santamaría I, Sainz C, Sánchez-Gregorio S, Garasa S, Ariz M, Ortiz-de-Solorzano C, Rodriguez-Ruiz ME, Perez-Gracia JL, Lozano MD, Echeveste JI, Sanmamed MF, Melero I. J Pathol. 2021 Oct; 2021 Aug 5. PMID: 34184758.
A Burned-Out CD8⁺ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy.Sanmamed MF, Nie X, Desai SS, Villaroel-Espindola F, Badri T, Zhao D, Kim AW, Ji L, Zhang T, Quinlan E, Cheng X, Han X, Vesely MD, Nassar AF, Sun J, Zhang Y, Kim TK, Wang J, Melero I, Herbst RS, Schalper KA, Chen L. Cancer Discov. 2021 Jul; 2021 Mar 3. PMID: 33658301.
Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non-Small Cell Lung Cancer.Datar IJ, Hauc SC, Desai S, Gianino N, Henick B, Liu Y, Syrigos K, Rimm DL, Kavathas P, Ferrone S, Schalper KA. Clin Cancer Res. 2021 May 15; 2021 Feb 18. PMID: 33602682.
IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy.Teijeira A, Garasa S, Ochoa MC, Villalba M, Olivera I, Cirella A, Eguren-Santamaria I, Berraondo P, Schalper KA, de Andrea CE, Sanmamed MF, Melero I. Clin Cancer Res. 2021 May 1; 2020 Dec 29. PMID: 33376096.
Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry.Martinez-Morilla S, Villarroel-Espindola F, Wong PF, Toki MI, Aung TN, Pelekanou V, Bourke-Martin B, Schalper KA, Kluger HM, Rimm DL. Clin Cancer Res. 2021 Apr 1; 2021 Jan 27. PMID: 33504554.
Graph of graphs analysis for multiplexed data with application to imaging mass cytometry.Lin YE, Shnitzer T, Talmon R, Villarroel-Espindola F, Desai S, Schalper K, Kluger Y. PLoS Comput Biol. 2021 Mar; 2021 Mar 29. PMID: 33780435.
Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.Alvarado-Cruz I, Mahmoud M, Khan M, Zhao S, Oeck S, Meas R, Clairmont K, Quintana V, Zhu Y, Porciuncula A, Wyatt H, Ma S, Shyr Y, Kong Y, LoRusso PM, Laverty D, Nagel ZD, Schalper KA, Krauthammer M, Sweasy JB. Biochem Pharmacol. 2021 Feb; 2020 Dec 4. PMID: 33285109.

2020

Overview of Lung Cancer Immunotherapy.Sanmamed MF, Eguren-Santamaria I, Schalper KA. Cancer J. 2020 Nov/Dec. PMID: 33298718.
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study.Lu C, Bera K, Wang X, Prasanna P, Xu J, Janowczyk A, Beig N, Yang M, Fu P, Lewis J, Choi H, Schmid RA, Berezowska S, Schalper K, Rimm D, Velcheti V, Madabhushi A. Lancet Digit Health. 2020 Nov; 2020 Oct 19. PMID: 33163952.
PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice.Eguren-Santamaria I, Sanmamed MF, Goldberg SB, Kluger HM, Idoate MA, Lu BY, Corral J, Schalper KA, Herbst RS, Gil-Bazo I. Clin Cancer Res. 2020 Aug 15; 2020 Apr 30. PMID: 32354698.
Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling.Zugazagoitia J, Gupta S, Liu Y, Fuhrman K, Gettinger S, Herbst RS, Schalper KA, Rimm DL. Clin Cancer Res. 2020 Aug 15; 2020 Apr 6. PMID: 32253229.
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.Remon J, Passiglia F, Ahn MJ, Barlesi F, Forde PM, Garon EB, Gettinger S, Goldberg SB, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper KA, Skoulidis F, Reck M, Adjei AA, Scagliotti GV. J Thorac Oncol. 2020 Jun; 2020 Mar 14. PMID: 32179179.
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity.Teijeira Á, Garasa S, Gato M, Alfaro C, Migueliz I, Cirella A, de Andrea C, Ochoa MC, Otano I, Etxeberria I, Andueza MP, Nieto CP, Resano L, Azpilikueta A, Allegretti M, de Pizzol M, Ponz-Sarvisé M, Rouzaut A, Sanmamed MF, Schalper K, Carleton M, Mellado M, Rodriguez-Ruiz ME, Berraondo P, Perez-Gracia JL, Melero I. Immunity. 2020 May 19; 2020 Apr 13. PMID: 32289253.
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.Taube JM, Akturk G, Angelo M, Engle EL, Gnjatic S, Greenbaum S, Greenwald NF, Hedvat CV, Hollmann TJ, Juco J, Parra ER, Rebelatto MC, Rimm DL, Rodriguez-Canales J, Schalper KA, Stack EC, Ferreira CS, Korski K, Lako A, Rodig SJ, Schenck E, Steele KE, Surace MJ, Tetzlaff MT, von Loga K, Wistuba II, Bifulco CB. J Immunother Cancer. 2020 May. PMID: 32414858.
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Lancet Oncol. 2020 May; 2020 Apr 3. PMID: 32251621.
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors.Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, Walsh AM, Baxi V, Pandya D, Baradet T, Locke D, Wu Q, Reilly TP, Phillips P, Nagineni V, Gianino N, Gu J, Zhao H, Perez-Gracia JL, Sanmamed MF, Melero I. Nat Med. 2020 May; 2020 May 11. PMID: 32405062.
Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma.LoRusso PM, Schalper K, Sosman J. Pigment Cell Melanoma Res. 2020 May; 2020 Mar 15. PMID: 31705737.
Effects of Radiation on the Tumor Microenvironment.Monjazeb AM, Schalper KA, Villarroel-Espindola F, Nguyen A, Shiao SL, Young K. Semin Radiat Oncol. 2020 Apr. PMID: 32381294.
Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.Liu Y, Zugazagoitia J, Ahmed FS, Henick BS, Gettinger SN, Herbst RS, Schalper KA, Rimm DL. Clin Cancer Res. 2020 Feb 15; 2019 Oct 15. PMID: 31615933.

2019

Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.Zugazagoitia J, Liu Y, Toki M, McGuire J, Ahmed FS, Henick BS, Gupta R, Gettinger SN, Herbst RS, Schalper KA, Rimm DL. J Thorac Oncol. 2019 Dec; 2019 Oct 9. PMID: 31605795.
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy).Ascierto PA, Bifulco C, Buonaguro L, Emens LA, Ferris RL, Fox BA, Delgoffe GM, Galon J, Gridelli C, Merlano M, Nathan P, Odunsi K, Okada H, Paulos CM, Pignata S, Schalper KA, Spranger S, Tortora G, Zarour H, Butterfield LH, Puzanov I. J Immunother Cancer. 2019 Nov 29; 2019 Nov 29. PMID: 31783779.
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?Nixon AB, Schalper KA, Jacobs I, Potluri S, Wang IM, Fleener C. J Immunother Cancer. 2019 Nov 27; 2019 Nov 27. PMID: 31775882.
Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology.Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Nat Rev Clin Oncol. 2019 Nov; 2019 Aug 9. PMID: 31399699.
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA. Clin Cancer Res. 2019 Aug 1; 2019 May 3. PMID: 31053602.
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Clin Cancer Res. 2019 Aug 1; 2019 Mar 1. PMID: 30824587.
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, Sosman JA, Schalper KA, Anders RA, Wang H, Hoyt C, Pardoll DM, Danilova L, Taube JM. JAMA Oncol. 2019 Aug 1. PMID: 31318407.
Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry.Carvajal-Hausdorf DE, Patsenker J, Stanton KP, Villarroel-Espindola F, Esch A, Montgomery RR, Psyrri A, Kalogeras KT, Kotoula V, Foutzilas G, Schalper KA, Kluger Y, Rimm DL. Clin Cancer Res. 2019 May 15; 2019 Feb 22. PMID: 30796036.
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA. J Immunother Cancer. 2019 Mar 8; 2019 Mar 8. PMID: 30850021.
Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non-Small Cell Lung Cancer.Corredor G, Wang X, Zhou Y, Lu C, Fu P, Syrigos K, Rimm DL, Yang M, Romero E, Schalper KA, Velcheti V, Madabhushi A. Clin Cancer Res. 2019 Mar 1; 2018 Sep 10. PMID: 30201760.
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, Berraondo P, Villarroel-Espindola F, Choi J, Gúrpide A, Giraldez M, Goicoechea I, Gallego Perez-Larraya J, Sanmamed MF, Perez-Gracia JL, Melero I. Nat Med. 2019 Mar; 2019 Feb 11. PMID: 30742120.
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, Chen L, Chen Y, Zhu G, Yin W, Zheng L, Zhou T, Badri T, Yao S, Zhu S, Boto A, Sznol M, Melero I, Vignali DAA, Schalper K, Chen L. Cell. 2019 Jan 10; 2018 Dec 20. PMID: 30580966.
Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O'Connor DJ, Méndez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahimi S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, Monjazeb AM. Nat Med. 2019 Jan; 2018 Nov 12. PMID: 30420753.

2018

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.Pelekanou V, Villarroel-Espindola F, Schalper KA, Pusztai L, Rimm DL. Breast Cancer Res. 2018 Dec 17; 2018 Dec 17. PMID: 30558648.
Immunodivergence in Metastatic Colorectal Cancer.de Andrea CE, Schalper KA, Sanmamed MF, Melero I. Cancer Cell. 2018 Dec 10. PMID: 30537510.
Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer.Altan M, Kidwell KM, Pelekanou V, Carvajal-Hausdorf DE, Schalper KA, Toki MI, Thomas DG, Sabel MS, Hayes DF, Rimm DL. NPJ Breast Cancer. 2018; 2018 Dec 10. PMID: 30564631.
Oncolytic virus immunotherapy: future prospects for oncology.Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. J Immunother Cancer. 2018 Dec 4; 2018 Dec 4. PMID: 30514385.
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.Toki MI, Mani N, Smithy JW, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Schalper K, Syrigos KN, Rimm DL. J Thorac Oncol. 2018 Dec; 2018 Sep 26. PMID: 30267840.
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.Gettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm DL, Chen L, Herbst RS, Schalper KA. Nat Commun. 2018 Aug 10; 2018 Aug 10. PMID: 30097571.
Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer.Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst RS. J Thorac Oncol. 2018 Jun; 2018 Mar 22. PMID: 29578107.
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.Villarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed M, Velcheti V, Syrigos K, Toki M, Zhao H, Chen L, Herbst RS, Schalper KA. Clin Cancer Res. 2018 Apr 1; 2017 Dec 4. PMID: 29203588.
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD. J Clin Oncol. 2018 Mar 1; 2018 Jan 16. PMID: 29337640.

2017

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Cancer Discov. 2017 Dec; 2017 Oct 12. PMID: 29025772.
Interleukin-8 in cancer pathogenesis, treatment and follow-up.Alfaro C, Sanmamed MF, Rodríguez-Ruiz ME, Teijeira Á, Oñate C, González Á, Ponz M, Schalper KA, Pérez-Gracia JL, Melero I. Cancer Treat Rev. 2017 Nov; 2017 Aug 31. PMID: 28866366.
Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.Khunger M, Hernandez AV, Pasupuleti V, Rakshit S, Pennell NA, Stevenson J, Mukhopadhyay S, Schalper K, Velcheti V. JCO Precis Oncol. 2017 Nov. PMID: 35172490.
Prediction of recurrence in early stage non-small cell lung cancer using computer extracted nuclear features from digital H&E images.Wang X, Janowczyk A, Zhou Y, Thawani R, Fu P, Schalper K, Velcheti V, Madabhushi A. Sci Rep. 2017 Oct 19; 2017 Oct 19. PMID: 29051570.
Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer.Carvajal-Hausdorf DE, Mani N, Velcheti V, Schalper KA, Rimm DL. J Immunother Cancer. 2017 Oct 17; 2017 Oct 17. PMID: 29037255.
B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.Altan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL. Clin Cancer Res. 2017 Sep 1; 2017 May 24. PMID: 28539467.
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I. Ann Oncol. 2017 Aug 1. PMID: 28595336.
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.Carvajal-Hausdorf DE, Schalper KA, Bai Y, Black J, Santin AD, Rimm DL. Gynecol Oncol. 2017 Apr; 2017 Feb 11. PMID: 28196634.
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.Rehman JA, Han G, Carvajal-Hausdorf DE, Wasserman BE, Pelekanou V, Mani NL, McLaughlin J, Schalper KA, Rimm DL. Mod Pathol. 2017 Mar; 2016 Nov 11. PMID: 27834350.
Strategies to design clinical studies to identify predictive biomarkers in cancer research.Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I. Cancer Treat Rev. 2017 Feb; 2016 Dec 30. PMID: 28088073.
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer.Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL. Clin Cancer Res. 2017 Jan 15; 2016 Jul 20. PMID: 27440266.

2016

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma.Toki MI, Carvajal-Hausdorf DE, Altan M, McLaughlin J, Henick B, Schalper KA, Syrigos KN, Rimm DL. J Thorac Oncol. 2016 Nov; 2016 Jul 20. PMID: 27449805.
Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Labiano S, Sanmamed MF, Azpilikueta A, Bolaños E, Sanchez-Paulete AR, Aznar MA, Rouzaut A, Schalper KA, Jure-Kunkel M, Melero I. Cancer Res. 2016 Oct 15; 2016 Aug 22. PMID: 27550452.
Automated measurement of estrogen receptor in breast cancer: a comparison of fluorescent and chromogenic methods of measurement.Zarrella ER, Coulter M, Welsh AW, Carvajal DE, Schalper KA, Harigopal M, Rimm DL, Neumeister VM. Lab Invest. 2016 Sep; 2016 Jun 27. PMID: 27348626.
Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer.Mani NL, Schalper KA, Hatzis C, Saglam O, Tavassoli F, Butler M, Chagpar AB, Pusztai L, Rimm DL. Breast Cancer Res. 2016 Jul 29; 2016 Jul 29. PMID: 27473061.
Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?Datar I, Schalper KA. Clin Cancer Res. 2016 Jul 15; 2016 Apr 13. PMID: 27076625.
Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research.Schalper KA, Kaftan E, Herbst RS. Clin Cancer Res. 2016 May 1; 2016 Mar 8. PMID: 26957559.
Basic Overview of Current Immunotherapy Approaches in Cancer.Velcheti V, Schalper K. Am Soc Clin Oncol Educ Book. 2016. PMID: 27249709.
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. JAMA Oncol. 2016 Jan. PMID: 26562159.

2015

Spironolactone inhibits the activity of the Na+/H+ exchanger in the aorta of mineralocorticoid-induced hypertensive rats.Carreño JE, Verdugo FJ, Contreras F, Montellano FA, Veloso S, Schalper KA, Sandoval M, Villanueva S, Marusic E, Irarrazabal CE. J Renin Angiotensin Aldosterone Syst. 2015 Dec; 2015 May 21. PMID: 25997821.
Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19.Barrera F, Azócar L, Molina H, Schalper KA, Ocares M, Liberona J, Villarroel L, Pimentel F, Pérez-Ayuso RM, Nervi F, Groen AK, Miquel JF. Ann Hepatol. 2015 Sep-Oct. PMID: 26256900.
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.Sanmamed MF, Rodriguez I, Schalper KA, Oñate C, Azpilikueta A, Rodriguez-Ruiz ME, Morales-Kastresana A, Labiano S, Pérez-Gracia JL, Martín-Algarra S, Alfaro C, Mazzolini G, Sarno F, Hidalgo M, Korman AJ, Jure-Kunkel M, Melero I. Cancer Res. 2015 Sep 1; 2015 Jun 25. PMID: 26113085.
Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.Carvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V, Fountzilas G, Rimm DL. J Natl Cancer Inst. 2015 Aug; 2015 May 19. PMID: 25991002.
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL. Cancer Immunol Res. 2015 Apr; 2014 Dec 19. PMID: 25527356.
Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic.Carvajal-Hausdorf DE, Schalper KA, Neumeister VM, Rimm DL. Lab Invest. 2015 Apr; 2014 Dec 15. PMID: 25502176.
Objective measurement and clinical significance of TILs in non-small cell lung cancer.Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL. J Natl Cancer Inst. 2015 Mar; 2015 Feb 3. PMID: 25650315.

2014

Unvalidated antibodies and misleading results.Rimm D, Schalper K, Pusztai L. Breast Cancer Res Treat. 2014 Sep; 2014 Aug 3. PMID: 25086631.
Possible role of hemichannels in cancer.Schalper KA, Carvajal-Hausdorf D, Oyarzo MP. Front Physiol. 2014; 2014 Jun 27. PMID: 25018732.
PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer.Schalper KA. Oncoimmunology. 2014; 2014 Jun 25. PMID: 25083339.
In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL. Clin Cancer Res. 2014 May 15; 2014 Mar 19. PMID: 24647569.
Automated objective determination of percentage of malignant nuclei for mutation testing.Viray H, Coulter M, Li K, Lane K, Madan A, Mitchell K, Schalper K, Hoyt C, Rimm DL. Appl Immunohistochem Mol Morphol. 2014 May-Jun. PMID: 24162261.
Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation.Rajbhandari P, Schalper KA, Solodin NM, Ellison-Zelski SJ, Ping Lu K, Rimm DL, Alarid ET. Oncogene. 2014 Mar 13; 2013 Apr 1. PMID: 23542176.
Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer.Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, Javle M. Gastrointest Cancer Res. 2014 Mar. PMID: 24799970.
A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.Schalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P. Arch Pathol Lab Med. 2014 Feb; 2013 Oct 28. PMID: 24164555.
Programmed death ligand-1 expression in non-small cell lung cancer.Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Lab Invest. 2014 Jan; 2013 Nov 11. PMID: 24217091.
[BRAF gene mutation in wild-type KRAS patients with colorectal cancers].Roa I, Game A, Bizama C, Schalper K. Rev Med Chil. 2014 Jan. PMID: 24861115.

2013

[Quality of DNA from archival pathological samples of gallbladder cancer].Roa I, de Toro G, Sánchez T, Slater J, Ziegler AM, Game A, Arellano L, Schalper K, de Aretxabala X. Rev Med Chil. 2013 Dec. PMID: 24728429.
[HER2 gene amplification and overexpression in advanced gastric cancer].Roa I, Slater J, Carvajal D, Schalper K, de Toro G, Ares R, Game A, León J, de Aretxabala X. Rev Med Chil. 2013 Nov. PMID: 24718467.
[KRAS gene mutation in colorectal cancer].Roa I, Sánchez T, Majlis A, Schalper K. Rev Med Chil. 2013 Sep. PMID: 24522420.
Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas.Viray H, Bradley WR, Schalper KA, Rimm DL, Gould Rothberg BE. Arch Pathol Lab Med. 2013 Aug. PMID: 23899062.
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1).Velcheti V, Rimm DL, Schalper KA. J Thorac Oncol. 2013 Jun. PMID: 23676558.